Oprah Winfrey is sparking a debate around weight, willpower and perception after the media mogul revealed her perceptions ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...

Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...